JP2022550434A5 - - Google Patents

Info

Publication number
JP2022550434A5
JP2022550434A5 JP2022520224A JP2022520224A JP2022550434A5 JP 2022550434 A5 JP2022550434 A5 JP 2022550434A5 JP 2022520224 A JP2022520224 A JP 2022520224A JP 2022520224 A JP2022520224 A JP 2022520224A JP 2022550434 A5 JP2022550434 A5 JP 2022550434A5
Authority
JP
Japan
Prior art keywords
antibody
abc
adc
modification
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550434A (ja
JP7671284B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/000038 external-priority patent/WO2021066869A1/en
Publication of JP2022550434A publication Critical patent/JP2022550434A/ja
Publication of JP2022550434A5 publication Critical patent/JP2022550434A5/ja
Priority to JP2025068989A priority Critical patent/JP2025105696A/ja
Application granted granted Critical
Publication of JP7671284B2 publication Critical patent/JP7671284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520224A 2019-10-04 2020-10-02 Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物 Active JP7671284B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025068989A JP2025105696A (ja) 2019-10-04 2025-04-18 Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962973475P 2019-10-04 2019-10-04
US62/973,475 2019-10-04
PCT/US2020/000038 WO2021066869A1 (en) 2019-10-04 2020-10-02 Antibody compositions comprising fc mutations and site-specific conjugation properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025068989A Division JP2025105696A (ja) 2019-10-04 2025-04-18 Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物

Publications (3)

Publication Number Publication Date
JP2022550434A JP2022550434A (ja) 2022-12-01
JP2022550434A5 true JP2022550434A5 (cg-RX-API-DMAC7.html) 2023-08-10
JP7671284B2 JP7671284B2 (ja) 2025-05-01

Family

ID=73172784

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520224A Active JP7671284B2 (ja) 2019-10-04 2020-10-02 Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物
JP2025068989A Pending JP2025105696A (ja) 2019-10-04 2025-04-18 Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025068989A Pending JP2025105696A (ja) 2019-10-04 2025-04-18 Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物

Country Status (11)

Country Link
US (3) US12662532B2 (cg-RX-API-DMAC7.html)
EP (1) EP4017542A1 (cg-RX-API-DMAC7.html)
JP (2) JP7671284B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079590A (cg-RX-API-DMAC7.html)
CN (2) CN120248121A (cg-RX-API-DMAC7.html)
AU (1) AU2020357550A1 (cg-RX-API-DMAC7.html)
CA (1) CA3154710A1 (cg-RX-API-DMAC7.html)
IL (1) IL291902A (cg-RX-API-DMAC7.html)
MX (1) MX2022003935A (cg-RX-API-DMAC7.html)
SA (1) SA522432146B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021066869A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024051762A1 (en) * 2022-09-07 2024-03-14 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-trop2/egfr antibodies and uses thereof
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2024163586A1 (en) * 2023-02-02 2024-08-08 University Of Washington Devices and methods for quantitative measurement of one or more analytes over a range of concentrations
KR20250161636A (ko) * 2023-03-27 2025-11-17 오비아이 파머 인코퍼레이티드 Trop2 접합된 생물학적 분자, 제약 조성물 및 방법
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途
CN121517545A (zh) * 2024-08-13 2026-02-13 菲鹏生物股份有限公司 一种Fc突变体及其用途

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
EP0953039B1 (en) 1996-10-15 2007-08-29 The Regents Of The University Of California Animal models of human prostate cancer progression
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1423431B1 (en) 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항-ctla-4 항체의 용도
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
CA2595169A1 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CN101360751B (zh) 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
PL2604693T3 (pl) 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
AU2012258907A1 (en) * 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
KR20200128601A (ko) 2011-05-27 2020-11-13 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
CA2871934C (en) 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
DK3151865T3 (da) 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
WO2016014551A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3424561B1 (en) 2016-03-25 2019-10-09 Neuboron Medtech Ltd. Boron neutron capture treating system and alpha-amino acid-like boron trifluoride compounds for use in treating tumors
FI20160191A7 (fi) 2016-07-29 2018-01-30 Matti Leo Antero Kokkonen Polkupyörän ja muiden ajoneuvojen renkaan puhkeamisen suoja
CA3046432A1 (en) 2016-12-13 2018-06-21 Astellas Pharma Inc. Anti-human cd73 antibody
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
JP7543134B2 (ja) 2017-10-03 2024-09-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング システイン操作された抗原結合分子
WO2019079357A1 (en) * 2017-10-17 2019-04-25 Silverback Therapeutics, Inc. Tnik modulators, conjugates, and uses thereof

Similar Documents

Publication Publication Date Title
JP2024174962A5 (cg-RX-API-DMAC7.html)
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
JP2014524748A5 (cg-RX-API-DMAC7.html)
NZ520907A (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
KR20010015817A (ko) 항-이디오타입 반응을 유도하는 능력이 강화된 변형된 항체
JP2020510039A5 (cg-RX-API-DMAC7.html)
JP2023085336A (ja) ミクログリアの活性化を抑制する方法
TW202330040A (zh) 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2022523530A5 (cg-RX-API-DMAC7.html)
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
JP2024516359A5 (cg-RX-API-DMAC7.html)
JP2025511401A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
CN103833712A (zh) 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
ES2286471T3 (es) Composiciones farmaceuticas antivirales.
CN101062041B (zh) 葫芦素新的医药用途
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN111971049A (zh) 促进免疫应答
JP2024521105A5 (cg-RX-API-DMAC7.html)
JP2024533109A5 (cg-RX-API-DMAC7.html)
CN1863512A (zh) 控释药物组合物及其制备方法
EP4188440A2 (en) Cd-3 antibodies for the treatment of coronavirus
JP2021527646A5 (cg-RX-API-DMAC7.html)
JP2025511403A5 (cg-RX-API-DMAC7.html)
WO2020108612A1 (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途